{"transactions":[{"id":1804392,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":110479,"kind":"person","name":"Hayon Yael","position":1,"cik":"0001817121","reported_name":"Hayon Yael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research & Development"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-08-17T20:30:28.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":35115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030 and options to purchase 250,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 9, 2032."}],"balance_after":35115,"derivative":{"exercise_price":1.99,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":35115},"source":{"system":"sec-edgar","filing":"0001104659-23-093069","document":"tm2324046-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093069/tm2324046-2_4seq1.xml","form_type":"4"}},{"id":1804391,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":110479,"kind":"person","name":"Hayon Yael","position":1,"cik":"0001817121","reported_name":"Hayon Yael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research & Development"}}],"security":"Common Stock","published_at":"2023-08-17T20:30:28.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":35115,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended (the \"Plan\"). The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":35115,"source":{"system":"sec-edgar","filing":"0001104659-23-093069","document":"tm2324046-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093069/tm2324046-2_4seq1.xml","form_type":"4"}},{"id":2162619,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":110479,"kind":"person","name":"Hayon Yael","position":1,"cik":"0001817121","reported_name":"Hayon Yael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research & Development"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:03:38.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030."}],"balance_after":250000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-22-098951","document":"tm2225460-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098951/tm2225460-8_4seq1.xml","form_type":"4"}},{"id":3086969,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":110479,"kind":"person","name":"Hayon Yael","position":1,"cik":"0001817121","reported_name":"Hayon Yael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research & Development"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-07-08T21:01:21.000Z","date":"2020-07-05","kind":"grant","acquired":true,"shares":129771,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."}],"balance_after":129771,"derivative":{"exercise_price":3.73,"expiration_date":"2030-07-05","underlying":"Common Stock","underlying_shares":129771},"source":{"system":"sec-edgar","filing":"0001104659-20-082116","document":"tm2024387d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920082116/tm2024387d2_4.xml","form_type":"4"}}]}